European Cancer Stem Cell Research Institute, Cardiff University School of Biosciences, Cardiff CF24 4HQ, UK.
Cells. 2019 Jul 13;8(7):715. doi: 10.3390/cells8070715.
Glioblastoma is the most lethal brain cancer in adults, with no known cure. This cancer is characterized by a pronounced genetic heterogeneity, but aberrant activation of receptor tyrosine kinase signaling is among the most frequent molecular alterations in glioblastoma. Somatic mutations of fibroblast growth factor receptors () are rare in these cancers, but many studies have documented that signaling through FGFRs impacts glioblastoma progression and patient survival. Small-molecule inhibitors of FGFR tyrosine kinases are currently being trialed, underlining the therapeutic potential of blocking this signaling pathway. Nevertheless, a comprehensive overview of the state of the art of the literature on FGFRs in glioblastoma is lacking. Here, we review the evidence for the biological functions of FGFRs in glioblastoma, as well as pharmacological approaches to targeting these receptors.
胶质母细胞瘤是成人中最致命的脑癌,目前尚无已知的治愈方法。这种癌症的特征是明显的遗传异质性,但受体酪氨酸激酶信号的异常激活是胶质母细胞瘤中最常见的分子改变之一。成纤维细胞生长因子受体 () 的体细胞突变在这些癌症中很少见,但许多研究已经证明 FGFRs 的信号转导会影响胶质母细胞瘤的进展和患者的生存。FGFR 酪氨酸激酶的小分子抑制剂目前正在进行临床试验,这突显了阻断这种信号通路的治疗潜力。然而,目前缺乏对胶质母细胞瘤中 FGFR 文献的全面概述。在这里,我们回顾了 FGFR 在胶质母细胞瘤中的生物学功能的证据,以及针对这些受体的药理学方法。